View Older Stories View More Recent Stories
-
Form SC 13G BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Biohaven Pharmaceutical Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13D Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D/A Dicerna Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Braeburn Announces Completion of $110 Million Financing
-
Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases
-
TARIS Biomedical® Announces $25M Series B Financing
-
Form SC 13D/A Dicerna Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D/A Dicerna Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G InflaRx N.V. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Scientists at TSRI and Synthorx Create the First Semi-Synthetic Organism to Encode and Translate Expanded Genetic Information into a Novel Protein with Different Non-natural Amino Acids
-
Laura Shawver, Ph.D., Appointed CEO of Synthorx
-
Medeor Therapeutics Raises $57 Million In Series B Financing
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Form SC 13G SUNESIS PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D/A KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Ivantis FDA Clinical Trial of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials
-
InflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell
-
Ivantis Completes Pre-Market Approval Submission for the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS)
-
Realm Therapeutics Announces Completion of $26 million Private Placement
-
PlacementTracker Publishes Q3 2017 Private Placement Market League Tables
-
Realm Therapeutics Announces $26 Million PIPE Financing
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
-
BioPharm America Offers More High-Level Opportunities for Networking With Global Life Science Executives at 2017 Edition
-
Form 4 G1 Therapeutics, Inc. For: May 22 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery
-
AB Science reports today its annual financials as of 31 December 2016 and provides an update on its activities
-
Ivantis Announces FDA Clearance to Initiate Clinical Trial of the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS) in Patients with Advanced Glaucoma
-
Form SC 13D/A Dicerna Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, LLC
-
Solid Biosciences Raises up to $50 Million in Series C Financing
-
Form 4 KalVista Pharmaceuticals For: Mar 23 Filed by: RA CAPITAL MANAGEMENT, LLC
-
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
-
Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board
-
Form 13F-HR/A RA CAPITAL MANAGEMENT, For: Dec 31
-
Form 13F-HR/A RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Strongbridge Biopharma Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A SANUWAVE Health, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Zynerba Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Protagonist Therapeutics Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A ACHILLION PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: RA CAPITAL MANAGEMENT, LLC

